Sequential VAD (vincristine, adriamycin [doxorubicin], dexamethasone) and VTD (velcade [bortezomib], thalidomide, dexamethasone) induction followed by HDT (high dose therapy) with ASCT (autologous stem cell transplant) and maintenance treatment with velcade for newly diagnosed MM (multiple myeloma)

Trial Profile

Sequential VAD (vincristine, adriamycin [doxorubicin], dexamethasone) and VTD (velcade [bortezomib], thalidomide, dexamethasone) induction followed by HDT (high dose therapy) with ASCT (autologous stem cell transplant) and maintenance treatment with velcade for newly diagnosed MM (multiple myeloma)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Autologous stem cell therapy; Bortezomib; Dexamethasone; Doxorubicin; Thalidomide; Vincristine
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Planned end date changed from 1 Jul 2008 to 1 Oct 2013 as reported by University Hospital Medical Information Network - Japan.
    • 01 Nov 2009 Additional lead trial centre and trial investigator identified as reported by University Hospital Medical Information Network - Japan record.
    • 01 Nov 2009 New source identified and integrated (University Hospital Medical Information Network - Japan).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top